Alnylam Pharmaceuticals/$ALNY
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
- Ticker
- $ALNY
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,500
- Headquarters
- Cambridge, United States
- Website
- www.alnylam.com
ALNY Metrics
BasicAdvanced
$20B
7.86
$19.29
0.27
-
Price and volume
Market cap
$20B
Beta
0.27
52-week high
$479.79
52-week low
$149.18
Average daily volume
2.4M
Financial strength
Current ratio
2.478
Quick ratio
2.265
Long term debt to equity
0.643
Total debt to equity
0.832
Interest coverage (TTM)
3.25%
Profitability
EBITDA (TTM)
1,033.027
Gross margin (TTM)
77.28%
Net profit margin (TTM)
52.85%
Operating margin (TTM)
19.50%
Effective tax rate (TTM)
-239.00%
Revenue per employee (TTM)
$2,010,000
Management effectiveness
Return on assets (TTM)
9.51%
Return on equity (TTM)
138.07%
Valuation
Price to earnings (TTM)
7.862
Price to revenue (TTM)
4.027
Price to book
5.63
Price to tangible book (TTM)
5.63
Price to free cash flow (TTM)
25.04
Free cash flow yield (TTM)
3.99%
Free cash flow per share (TTM)
6.056
Growth
Revenue change (TTM)
56.17%
Earnings per share change (TTM)
2,056.93%
3-year revenue growth (CAGR)
42.74%
10-year revenue growth (CAGR)
63.26%
3-year earnings per share growth (CAGR)
67.37%
10-year earnings per share growth (CAGR)
15.55%
What the Analysts think about ALNY
Analyst ratings (Buy, Hold, Sell) for Alnylam Pharmaceuticals stock.
Analyst projections of the future price of Alnylam Pharmaceuticals stock.
Bulls say / Bears say
Third-quarter 2026 product revenue rose 52% year on year to $1.29 billion, with TTR revenue up 59% as Amvuttra demand continued to expand. This gives Alnylam a fast-growing commercial base to fund its next stage of development. (Business Wire)
Early Phase 1 data for brezosiran showed dose-dependent lowering of mutant huntingtin, with reductions of up to 64% on average in the highest dose group and no concerning safety trends reported so far. A pivotal study is planned for 2027, offering a potential growth avenue beyond Alnylam’s TTR franchise, though clinical benefit remains unproven. (Alnylam Pharmaceuticals)
Alnylam raised its 2026 collaboration and royalty revenue outlook to $575–625 million, mainly on stronger expected royalties from Novartis’ Leqvio. This provides a source of revenue alongside sales of Alnylam’s own medicines. (Alnylam Pharmaceuticals)
In July, management cut its 2026 TTR revenue outlook by $200 million at the midpoint after second-line demand for Amvuttra moderated from an initial surge. The reset shows that early launch momentum was not a reliable guide to ongoing demand. (Alnylam Pharmaceuticals)
A rival TTR-silencing drug failed to show a statistically significant reduction in cardiovascular events or death in a Phase 3 trial, raising questions about the added benefit of silencing on top of stabiliser treatment. That result may also increase uncertainty around Alnylam’s next-generation TTR programme. (BioPharma Dive)
The FDA challenged Amvuttra website claims about longer survival, saying they relied on open-label extension data without a concurrent placebo group and could give a misleading impression of efficacy. The scrutiny adds promotional-compliance and reputational risk around Alnylam’s leading product. (Fierce Pharma)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
ALNY Financial Performance
Revenues and expenses
ALNY Earnings Performance
Company profitability
Upcoming events
No upcoming events
ALNY News
AllArticlesVideos
Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM
Business Wire2 days ago
Alnylam Announces $1 Billion Share Repurchase Program and Change in Commercial Leadership
Business Wire7 days ago
Alnylam Pharmaceuticals Q3 Earnings Call Highlights
MarketBeat2 weeks ago
Funds containing ALNY
AllUSDEURGBP
Fund name | Fund size | $ALNY weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 1.31% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 1.31% |
iShares MSCI World Health Care Sector Advanced£WHCA | $362M | 0.31% |
iShares MSCI World Health Care Sector Advanced€CBUF | $683M | 0.31% |
SPDR MSCI World Health Care£HEAW | $708M | 0.23% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.